Santen China signs exclusive distribution and promotion agreement for five marketed Glaucoma Eyedrops products in the Chinese Mainland. April 17, 2026 - Osaka, Japan - Santen Pharmaceutical Co., Ltd. (hereinafter Santen) announced today that Santen China has entered into a distribution and promotion agreement with AbbVie for five marketed glaucoma eyedrops in the Chinese Mainland. Under the agreement, Santen China will receive exclusive distribution rights and conduct promotional activities in the Chinese Mainland for Glaucoma Eyedrops Alphagan(R), AlphaganP(R), Lumigan(R), Ganfort(R) and Combigan(R). A pillar of AbbVie's glaucoma eyedrop product portfolio, the brimonidine tartrate ophthalmic solution (Alphagan(R) and AlphaganP(R) features a dual intraocular pressure (IOP)-lowering effect that suppresses aqueous humor production and promotes aqueous humor outflow via the uveoscleral pathway; it is recommended as one of the first-line treatments under Asia-Pacific Glaucoma Society guidelines.[1] These products will synergize with existing Santen prostaglandin-related products while creating a complementary, multi-MoA (Mechanism of Action) glaucoma portfolio and strengthening the Company's business foundation in the China market. Glaucoma is a disease in which the optic nerve is damaged by increased IOP, causing progressive visual field loss; if not treated appropriately, it can lead to blindness.[2,3] As of 2020, the number of patients with primary glaucoma worldwide exceeded 76 million, and this number is expected to exceed 100 million by 2040.[4] The number of glaucoma patients in China numbered more than 21.8 million, leading to 5.67 million cases of blindness as of 2020.[2] By fully leveraging its proven strong commercial presence in China's glaucoma market, Santen will capitalize on this agreement with AbbVie to unleash the growth potential of the glaucoma products. While focusing on addressing clinical challenges in glaucoma treatment, Santen is committed to providing eye care professionals with new therapeutic strategies and approaches, empowering them to elevate the standard of glaucoma treatment in China, and ultimately benefit millions of patients. References * Asia-Pacific Glaucoma Guidelines, 4th Edition. 2024 * Chinese Glaucoma Guideline (2020) [J]. Chinese Journal of Ophthalmology, 2020, 56(8): 573-586. * Weinreb RN, et al. JAMA. 2014;311(18):1901-1911. * Tham YC, et al. Ophthalmology. 2014;121(11):2081-2090. About Santen Santen is a global pharmaceutical company committed to advancing eye health and improving lives through better vision. Founded in 1890 in Osaka, Japan, Santen makes use of more than 135 years of experience in research and development, manufacturing, and marketing of pharmaceuticals and medical devices to help people around the globe maintain and improve their eye health. Santen focuses exclusively on eye health and its portfolio includes glaucoma, dry eye, infection, allergy, age-related macular degeneration, and myopia. Santen's products and services are available in more than 60 countries and regions. Guided by its Core Principle "Tenki ni sanyo suru" - Exploring the secrets and mechanisms of nature in order to contribute to people's health - Santen combines its expertise with deep patient focus to contribute to the realization of "Happiness with Vision." For more information, please visit https://www.santen.com/en. About AbbVie Founded in 2013, AbbVie is a top 5 research-based global biopharmaceutical company headquartered in North Chicago, Illinois, the USA. AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. Santen Pharmaceutical Co. strive to have a remarkable impact on people's lives across several key therapeutic areas - immunology, oncology, neuroscience, and eye care - and products and services in its Allergan Aesthetics portfolio. Contact Corporate Communications Santen Pharmaceutical Co., Ltd. E-mail: [email protected] This press release has been published in Japanese, Simplified Chinese and English languages and in the event of any inconsistency, the English version shall prevail.

Rohto Pharmaceutical stock: A stable leader in Japan's eye care and OTC market with global expansion potential. 03.04.2026 - 09:39:13 | ad-hoc-news.de Rohto Pharmaceutical Co., Ltd. (ISIN: JP3982400008) stands as a key player in over-the-counter pharmaceuticals and cosmetics, particularly known for eye care products. North American investors may find value in its steady domestic performance and growing international footprint amid rising global demand for self-care health solutions. Rohto Pharmaceutical Co., Ltd. operates as a prominent Japanese firm focused on over-the-counter drugs, cosmetics, and functional foods. The company holds a strong position in eye drops, skincare, and medicated products, serving consumers seeking quick-relief solutions for everyday health needs. Listed on the Tokyo Stock Exchange under ticker 4527 with ISIN JP3982400008, Rohto trades in Japanese yen. Its business model emphasizes research-driven innovation combined with efficient manufacturing and wide distribution networks. As of: 03.04.2026 By Elena Marcus, Senior Financial Editor at NorthStar Market Insights: Rohto Pharmaceutical exemplifies disciplined growth in the consumer health sector, balancing tradition with targeted global outreach. Core business and product portfolio. Official source All current information on Rohto Pharmaceutical directly from the company's official website. Rohto's flagship products include the Z! series of eye drops, which target dryness, fatigue, and allergies. These items dominate Japan's market due to their fast-acting formulas and trusted brand reputation built over decades. The company also offers skincare lines like Melano CC vitamin C serum and Obagi, which has gained traction internationally. Functional foods and medicated shampoos round out the portfolio, addressing consumer needs in personal care. Manufacturing occurs primarily in Japan with facilities optimized for high-volume production. Rohto invests in R&D to develop proprietary ingredients, ensuring product differentiation in competitive categories. Sales channels span pharmacies, convenience stores, and e-commerce platforms. This multi-channel approach supports consistent revenue streams even during economic fluctuations. Market position and competitive landscape. Sentiment and reactions In Japan, Rohto competes with firms like Lion Corporation and Santen Pharmaceutical in the eye care segment. Its market share remains robust, supported by brand loyalty and frequent product refreshes. Globally, Rohto expands through subsidiaries in Asia, Europe, and North America. The acquisition of interests in brands like Obagi positions it against larger players such as L'Oréal and Procter & Gamble in cosmetics. Rohto differentiates via science-backed formulations. For instance, its eye drops incorporate menthol and vitamins, offering relief not matched by generic alternatives. Distribution strength in Southeast Asia bolsters growth. Partnerships with local retailers enhance accessibility in high-population markets like Indonesia and Vietnam. The company's focus on OTC products avoids prescription drug complexities. This regulatory advantage allows quicker market entry and lower compliance costs. Financial health and performance drivers. Rohto maintains steady profitability through cost controls and premium pricing. Its balance sheet reflects low debt levels, providing flexibility for investments. Revenue derives mostly from Japan, with international sales growing steadily. Export of eye care and skincare products drives overseas expansion without heavy localization costs. Operating margins benefit from economies of scale in production. Efficient supply chains minimize disruptions, even amid global logistics challenges. Dividend policy supports shareholder returns. Consistent payouts appeal to income-focused investors seeking stability in volatile markets. R&D expenditure focuses on consumer trends like anti-aging and digital eye strain. These align with demographic shifts in aging populations across Asia. Strategic initiatives and growth catalysts. Rohto pursues overseas expansion via joint ventures and acquisitions. Entry into the U.S. market through Obagi leverages demand for premium skincare. Digital transformation enhances e-commerce capabilities. Online sales platforms cater to younger consumers preferring direct-to-consumer models. Sustainability efforts include eco-friendly packaging. This resonates with global trends toward responsible consumption, potentially opening premium segments. Innovation pipelines feature new eye care solutions for screen users. With rising remote work, such products address a persistent need. Partnerships with tech firms explore wearable health devices. Integration of pharma with tech could create future revenue streams. Relevance for North American investors. Further developments, updates, and context on the stock can be explored quickly through the linked overview pages. North American investors gain exposure to Japan's consumer health boom via Rohto. The stock offers diversification into Asia's stable pharma sector. U.S. presence through Obagi provides a foothold in the $100 billion skincare market. Growth here could accelerate returns for international holders. Currency dynamics play a role; a weaker yen enhances repatriated earnings. Hedging strategies mitigate forex risks for global portfolios. Rohto's defensive qualities suit conservative allocations. Demand for OTC products persists across economic cycles, unlike cyclical sectors. Accessibility via OTC markets or ADRs simplifies investment. Monitoring U.S. sales milestones offers clear catalysts for value appreciation. Risks and key questions for investors. Regulatory changes in Japan could impact OTC approvals. Stricter guidelines on ingredients pose compliance challenges. Competition intensifies from domestic and global rivals. Maintaining market share requires ongoing innovation investment. Currency fluctuations affect reported results. A strengthening yen might pressure margins for export-focused growth. Supply chain dependencies on raw materials expose to price volatility. Diversification efforts mitigate but do not eliminate this risk. Geopolitical tensions in Asia could disrupt expansion. Investors should track regional stability for international revenue projections. Consumer shifts toward natural products challenge synthetic formulas. Rohto's adaptation speed will determine competitive edge. Overall, Rohto Pharmaceutical stock presents a balanced opportunity. Its entrenched position supports long-term holding, with vigilance on global execution key. Disclaimer: Not investment advice. Stocks are volatile financial instruments. Rohto pharmaceutical-aktie: kaufen oder verkaufen?! Neue Rohto pharmaceutical-analyse vom 13. April liefert die antwort: Die neusten Rohto Pharmaceutical-Zahlen sprechen eine klare Sprache: Dringender Handlungsbedarf für Rohto Pharmaceutical-Aktionäre. Lohnt sich ein Einstieg oder sollten Sie lieber verkaufen? In der aktuellen Gratis-Analyse vom 13. April erfahren Sie was jetzt zu tun ist. Seit 2005 liefert der Börsenbrief trading-notes verlässliche Anlage-Empfehlungen - dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren. Für. Immer. Kostenlos. en | JP3982400008 | ROHTO PHARMACEUTICAL CO LTD | boerse | 69062988 | bgmi

Notice of Board of Director and Corporate auditor nominations. March 19, 2026, Osaka, Japan - Santen Pharmaceutical Co., Ltd. (hereinafter Santen) at a Board of Directors meeting held March 19, 2026, resolved to propose the following candidates of the Board of Directors, which will be submitted for approval at the 114th Annual General Meeting of Shareholders and the Board of Directors to be held in June 2026. Please note that no changes to Corporate Auditors have been proposed. Members of the Board of Directors (After the 114th Annual General Meeting of Shareholders scheduled to be held in June 2026) [Directors] | / | Name | New position | Current position | | Reappointed | Takeshi Ito | Representative Director of the Board, President, Chief Executive Officer | Representative Director of the Board, President, Chief Executive Officer | | Rie Nakajima | Member of the Board, Corporate Officer Chief Operating Officer | Member of the Board, Corporate Officer Chief Operating Officer | | Ippei Kurihara | Member of the Board, Corporate Officer Head of Japan Business Global Commercial Strategy | Member of the Board, Corporate Officer Head of Japan Business Global Commercial Strategy | | Masahiko Ikaga | Member of the Board* | Member of the Board* | | Minoru Kikuoka | Member of the Board* | Member of the Board* | | Yukiko Kuroda | Member of the Board* | Member of the Board* | | Newly appointed | Tetsuya Uekusa | Member of the Board* | - | *Outside Directors and independent officers as designated by the Tokyo Stock Exchange About Santen Santen is a global pharmaceutical company committed to advancing eye health and improving lives through better vision. Founded in 1890 in Osaka, Japan, Santen makes use of more than 135 years of experience in research and development, manufacturing, and marketing of pharmaceuticals and medical devices to help people around the globe maintain and improve their eye health. Santen focuses exclusively on eye health and its portfolio includes glaucoma, dry eye, infection, allergy, age-related macular degeneration, and myopia. Santen's products and services are available in more than 60 countries and regions. Guided by its Core Principle "Tenki ni sanyo suru" - Exploring the secrets and mechanisms of nature in order to contribute to people's health - Santen combines its expertise with deep patient focus to contribute to the realization of "Happiness with Vision." For more information, please visit https://www.santen.com/en. Contact Corporate Communications Santen Pharmaceutical Co., Ltd. E-mail: [email protected]